Sherif Iskander, MD
Cardiovascular Disease · Tyler, TXNPI 1255321980
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $37,790 of the $57,802 with a category attached, or 65.4%. 35 manufacturers reported payments, led by Lilly USA, LLC at 31.1% of the total. Reporting peaked in 2019 at $45,471 and has fallen 97.9% since, to $941 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $119.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$18K
- Novartis$15K
- Boehringer Ingelheim$14K
- Impulse Dynamics (USA) Inc.$2K
- Johnson & Johnson$1K
- Biotronik Inc.$1K
- plus $7K from 29 others
Across 2 payments — averaging $7089.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$14K
What the payments were for
- Consulting fees$4,8008%
- Speaking & faculty fees$37,79065%
- Travel & lodging$1,9553%
- Food & beverage$13,13723%
- Education$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 30 | $17,980 |
| Novartis | 107 | $14,864 |
| Boehringer Ingelheim | 29 | $13,763 |
| Impulse Dynamics (USA) Inc. | 23 | $1,616 |
| Johnson & Johnson | 44 | $1,192 |
| Biotronik Inc. | 24 | $1,086 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 28 | $715 |
| Merck | 34 | $614 |
| AstraZeneca | 12 | $609 |
| Amgen | 22 | $526 |
| Alnylam Pharmaceuticals Inc. | 5 | $469 |
| Pfizer | 25 | $453 |
| E.r. Squibb & Sons, L.L.C. | 16 | $419 |
| Abiomed | 4 | $394 |
| Abbott | 4 | $328 |
| Medtronic | 3 | $303 |
| Angiodynamics, Inc. | 6 | $289 |
| Sanofi-aventis U.S. LLC | 8 | $220 |
| Novo Nordisk | 10 | $202 |
| Lexicon Pharmaceuticals, Inc. | 5 | $194 |
| Astellas Pharma US Inc | 8 | $194 |
| Atricure, Inc. | 3 | $192 |
| Lundbeck LLC | 4 | $180 |
| Shockwave Medical, Inc | 1 | $168 |
| Philips North America LLC | 6 | $150 |
| Heartflow, Inc. | 1 | $137 |
| Gilead | 9 | $130 |
| Bayer | 2 | $117 |
| Jazz Pharmaceuticals Inc. | 2 | $110 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| Terumo Medical Corporation | 1 | $45 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Cvrx, Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $14 |
| Siemens Medical Solutions USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$29,854
- ENTRESTO$13,440
- OPTIMIZER$496
- XARELTO$488
- OPTIMIZER SMART SYSTEM$372
- ONPATTRO$344
- FARXIGA$335
- ELIQUIS$192
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$168
- SYMPLICITY G3$153
- FFRct$137
- MitraClip$131
- NORTHERA$129
- Inpefa$124
- ACC2 CARDIAC CRYOSURGICAL SYSTEM$123
- ATRICURE ATRICLIP LAA EXCLUSION$123
- Impella$122
- MULTAQ$122
- Repatha$116
- AMVUTTRA$107
How this compares
$57,802 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 202 | $187,643 |
| EntrestoSacubitril/Valsartan | 181 | $183,673 |
| XareltoRivaroxaban | 74 | $74,484 |
| FarxigaDapagliflozin Propanediol | 101 | $70,514 |
| JardianceEmpagliflozin | 26 | $34,966 |
| Ranolazine ErRanolazine | 242 | $19,565 |
| BrilintaTicagrelor | 22 | $17,320 |
| Repatha SureclickEvolocumab | 16 | $11,813 |
| Propafenone Hcl ErPropafenone Hcl | 37 | $8,516 |
| Bisoprolol Fumarate | 274 | $5,721 |
| Metoprolol Succinate | 363 | $5,023 |
| Losartan Potassium | 518 | $4,758 |
| Rosuvastatin Calcium | 270 | $4,029 |
| Hydralazine Hcl | 217 | $3,780 |
| Amlodipine Besylate | 517 | $3,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $453 | $187,643202 claims |
| NovartisEntresto | $14,864 | $183,673181 claims |
| AstraZenecaFarxiga, Brilinta | $609 | $87,834123 claims |
| Johnson & JohnsonXarelto | $1,192 | $74,48474 claims |
| Boehringer IngelheimJardiance | $13,763 | $34,96626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Tyler
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.